Construct design, production, and characterization of *Plasmodium falciparum* 48/45 R0.6C subunit protein produced in *Lactococcus lactis* as candidate vaccine

Susheel K. Singh1,2,3, Will Roeffen4, Ulrik H. Mistarz5, Bishwanath Kumar Chourasia1,2,3, Fen Yang5, Kasper D. Rand5, Robert W. Sauerwein6 and Michael Theisen1,2,3*

**Abstract**

**Background:** The sexual stages of *Plasmodium falciparum* are responsible for the spread of the parasite in malaria endemic areas. The cysteine-rich *Pf*s48/45 protein, exposed on the surface of sexual stages, is one of the most advanced antigens for inclusion into a vaccine that will block transmission. However, clinical *Pf*s48/45 sub-unit vaccine development has been hampered by the inability to produce high yields of recombinant protein as the native structure is required for the induction of functional transmission-blocking (TB) antibodies. We have investigated a downstream purification process of a sub-unit (R0.6C) fragment representing the C-terminal 6-Cys domain of *Pf*s48/45 (6C) genetically fused to the R0 region (R0) of asexual stage Glutamate Rich Protein expressed in *Lactococcus lactis*.

**Results:** A series of R0.6C fusion proteins containing features, which aim to increase expression levels or to facilitate protein purification, were evaluated at small scale. None of these modifications affected the overall yield of recombinant protein. Consequently, R0.6C with a C-terminal his tag was used for upstream and downstream process development. A simple work-flow was developed consisting of batch fermentation followed by two purification steps. As such, the recombinant protein was purified to homogeneity. The composition of the final product was verified by HPLC, mass spectrometry, SDS-PAGE and Western blotting with conformation dependent antibodies against *Pf*s48/45. The recombinant protein induced high levels of functional TB antibodies in rats.

**Conclusions:** The established production and purification process of the R0.6C fusion protein provide a strong basis for further clinical development of this candidate transmission blocking malaria vaccine.

**Keywords:** *Plasmodium falciparum*, Malaria, Transmission blocking, *Pf*s48/45, Batch fermentation and *Lactococcus lactis*

**Background**

The transmission of *Plasmodium falciparum* malaria from one person to another requires the production of male and female gametocytes in the human host that can be taken up by blood-feeding mosquitoes. Recent studies have indicated that a large proportion of individuals in malaria endemic areas carry gametocytes and may contribute to malaria transmission [1]. Control strategies that confer prolonged protection including vaccines, are therefore needed to effectively block malaria transmission at the population level [2]. *P. falciparum* *Pf*s48/45 is one of the leading transmission blocking vaccine (TBV) candidates that has entered the pipeline of clinical development (for a review see [3]). This protein is relatively cysteine-rich with multiple disulfide bonds that result in antibody epitopes which are dependent on properly folded tertiary structures rather than linear amino acid sequences. Functional in vitro
studies have identified the C-terminal portion of \( Pfs48/45 \) (6C) containing three disulfide bonds as major target of transmission blocking (TB) antibodies [4]. This \( Pfs48/45 \) region is targeted by a monoclonal antibody (mAb) mAb45.1 which promotes strong TB activity in the standard membrane feeding assay (SMFA), the gold standard for assessing transmission blockade ex vivo [5–8].

The production of \( Pfs48/45 \) in bacterial and eukaryotic expression systems has been problematic due to insufficient protein folding capabilities of these systems. Proper folding of cysteine-rich \( Pfs48/45 \) depends on correct formation of disulfide bridges. Since eukaryotic cells possess a sophisticated machinery for disulfide bond formation, recombinant \( Pfs48/45 \) has been produced in a range of Baculovirus (\textit{Spodoptera frugiperda} S9) cells [9], \textit{Vaccinia} virus [10], \textit{Saccharomyces cerevisiae} [11], and \textit{Pichia pastoris} [11], \textit{Chlamydomonas reinhardtii} [12], and \textit{Nicotiana benthamiana} [13]. However, protein yields were rather low and in those cases where expression was successful, there was limited reactivity with mAbs against conformational TB epitopes. The bacterial \textit{Lactococcus lactis} expression system represents a significant advancement in the production of recombinant \( Pfs48/45 \) [14, 15]. \textit{L. lactis} cell factories generally recognized as safe (GRAS status) are well suited for the production of heterologous proteins and used for a wealth of food applications. In the recent years, \textit{L. lactis} has also been used in modern biotechnology within the fields of mucosal delivery [16] generation of self-adjuvanting bacterium-like particles [17] and recombinant proteins (reviewed in [18]). \textit{L. lactis} do not produce endotoxins or extracellular proteases. Moreover, gene expression can be controlled by a set of tightly regulated promoters in a simple and scalable fermentation process from a few ml up to thousands of liters. Recombinant proteins can be secreted into the culture medium in the absence of spore formation which clearly facilitates downstream processing. Accordingly, \textit{L. lactis} has been used for the manufacturing of the GMZ2 malaria vaccine candidate [19–22].

To advance development of a protein-vaccine based on \( Pfs48/45 \), we established a manufacturing process for R0.6C in \textit{L. lactis}. The product was characterized by mass spectrometry (MS)-based and by HPLC-based methods and tested for functional immunogenicity in rats. The specificity of induced antibodies was assessed by ELISA, and functional capacity for transmission blockade in the standard membrane-feeding assay (SMFA).

**Results**

**Molecular design and expression of chimeric GLURP-\( Pfs48/45 \) fusion proteins**

We designed a set of fusion proteins (Fig. 1a) consisting of the \( Pfs48/45 \) 6-Cys domain to address whether expression levels of secreted R0.6C was affected by: (1) codon optimization, (2) different signal peptides, and (3) the presence and/or position of a range of affinity-tags. All constructs were transformed into \textit{L. lactis} MG1363 and grown in 5 ml of LAB medium at 30 °C without shaking. Firstly, the codon optimized construct generated the same amount of recombinant R0.6C fusion protein as did the non-optimized construct (Fig. 1b, compare lanes 1 and 2). Secondly, we found that protein yields were similar between constructs with and without a His-tag (Fig. 1b, compare lanes 1 and 3), suggesting that the His-tag per se does not affect production yields of R0.6C. Thirdly, fusion proteins containing tags that can be used for various conjugation strategies including the SpyTag-spyCatcher technology [23, 24] and Streptavidin-mSA mediated conjugation to bacterial outer membrane vesicles [25] were explored. The addition of these tags to the N- or C-terminal end of R0.6C did not affect over all expression levels (Fig. 1b, lanes 5, 6, and 7). Finally, we showed that a native USP45 signal peptide derived from an abundantly secreted \textit{L. lactis} protein did not increase protein yields in culture supernatants (Fig. 1b, lanes 1 and 8).

**Production of recombinant R0.6C in bioreactor**

Since all constructs tested gave similar yields, we choose R0.6C with a C-terminal His-tag (Fig. 1a, construct no. 1) for optimization of fermentation in lab-scale bioreactors. The generation of R0.6C showed a substantial accumulation in the culture medium at 10–15 h post inoculation (Fig. 2a). Recombinant R0.6C was produced as an intact fusion protein as indicated by Coomassie staining (Fig. 2b upper panel) and immune blotting with an antibody against the C-terminal his-tag (Fig. 2b, middle panel). The secreted protein was properly folded as indicated by immune blotting with the conformation dependent mAb45.1 (Fig. 2b lower panel). Subsequently, a robust workflow for production was developed by growing \textit{L. lactis} MG1363 expressing R0.6C in a 1 l stirred bioreactor for 15 h at 30 °C (Fig. 3a). The non-oxidative fermentation resulted in rapid acidification due to the production of lactate. Acidification eventually inhibits cell growth but also induces protein expression by activating the P170 promoter [18]. In order to optimize both cell growth and promoter activity, the fermenter was equipped with a pH electrode to monitor and control pH by addition of 2 M NaOH. The culture medium was also supplemented with 5 mM cysteine and 0.5 mM cystine which, together with the micro-aerobic milieu, is essential for high yield production of disulfide-bonded recombinant protein.

**Purification of recombinant R0.6C**

Supernatants were concentrated and buffer exchanged for phosphate buffered saline (PBS) pH 7.4 supplemented
Singh et al. Microb Cell Fact (2017) 16:97

with 15 mM imidazole. R0.6C was captured on a His-Trap HP column and bound protein was eluted with a linear imidazole gradient (Fig. 3b). Fractions containing recombinant R0.6C were analyzed by SDS-PAGE and by mAb45.1 sandwich ELISA (Fig. 3b). Fractions containing high concentration of immune reactive protein were pooled and loaded on an anion ion-exchange chromatography column, to separate protein species with native and non-native disulfide bonds (Fig. 3c). Fractions (P1) containing mAb45.1 reactive monomer were pooled with a major band of monomeric protein strongly reactive to mAb45.1 (Fig. 3d). This R0.6C fraction contained >80% properly folded Pf48/45 relative to immune purified reference material (Fig. 3e and Additional file 1). The same work-flow for R0.6C constructs tagged with SpyTag, SpyCatcher, and mSA at their N-terminal ends resulted in similar yields of properly folded R0.6C.

Mass spectrometry analysis of R0.6C

The mass of non-reduced and reduced full-length R0.6C was 71325.4 and 71331.3 Da as determined by LC–MS respectively (Additional file 2a, b). This molecular weight corresponds well to the predicted value of 71331.01 Da assuming that the fusion protein contains the vector-encoded amino acid residues A-E-R-S at the N-terminal end and a 6xHis-tag at the C-terminal end. Reduction of R0.6C resulted in a shift in the measured mass of the intact protein by approximately 6 Da, consistent with the presence of 3 disulfide bonds. The correct primary structure of R0.6C was further verified through
MS/MS sequencing of 39 tryptic peptides derived from reduced R0.6C (Additional file 2c). These peptides cover 85% of the protein confirming that the purified R0.6C fusion protein was intact with the predicted amino acid residues corresponding to a full-length GLURP27–500–Pfs48/45s48/45291–428 fusion protein.

The disulfide connectivity of R0.6C was characterized by analyzing tryptic peptides by LC–MS/MS. Four peptides were not found in non-reduced R0.6C sample, indicating their involvement in cross-linking, whereas, two peptides were exclusively present in non-reduced R0.6C, referred to as XL-peptides I and II (Fig. 4a, b, respectively). The identity of these cross-linked peptides was established by manual inspection of masses of peptide precursors and the corresponding fragment ions (Fig. 4d for peptide I). In XL-peptide I, C492 formed a disulfide bond with C521. In XL-peptide II, C604 was disulfide bonded to C546 or C538, whereas C606 formed a disulfide bond with the other cysteine residue. Due to the close proximity of C604 and C606 it was only possible to resolve the disulfide connectivity to either of the two cysteine residues. Several control peptides without cysteine residues were monitored simultaneously with an example shown in (Fig. 4d). A diagram of the disulfide connectivity of the correctly folded Pfs48/45-6C region is shown in (Fig. 4e).

Size-exclusion and reversed-phase HPLC analysis of purified R0.6C

A Pfs48/45-based vaccine antigen should consist of properly folded monomer. The final R0.6C batch elutes as a single peak at 42.5 min by analytical size exclusion chromatography (SEC), representing the active monomer state (Fig. 5a). Subsequent reversed-phase chromatography analysis showed a main peak with a retention time of 17.0 min and a smaller peak at approximately 16.5 min (Fig. 5b). The latter was absent in reference material containing immune-purified R0.6C (data not shown) suggesting that this peak corresponds to host cell proteins or a minor fraction of product-related impurities. The overall purity of R0.6C as determined by RP-HPLC was 87%.

Stability of recombinant R0.6C

Finally, we assessed the chemical and physical stability of the recombinant protein for 30 days at 4 °C. There was no appreciable degradation at any time-point when analyzed by SDS-PAGE, immunoblotting with mAb45.1 (Additional file 3). The bioactivity of the protein was maintained throughout the experiment as determined by the sandwich-ELISA (Additional file 3).

Immunogenicity of recombinant R0.6C

To ascertain that R0.6C elicit adequate levels of gametocyte-specific antibodies with the capacity to inhibit parasite fertilization, Wistar rats (N = 8) were immunized 3 times at 3-week intervals with increasing doses (2.5, 10, and 25 μg) of R0.6C inducing similar levels of vaccine-specific (Fig. 6a), epitope I-specific (Fig. 6b), and 6C-specific (Fig. 6c) antibodies. There was a strong correlation between 6C- and epitope I specific antibody levels (Fig. 6d) suggesting that epitope I is the main epitope in the 6-Cys domain of Pfs48/45. Collectively, these results demonstrate that R0.6C gives an adequate presentation of conformational epitope(s) in Pfs48/45. Serum pools from
each dosing group were tested for functional activity in the SMFA showing >99% TB activity at a 1/9 dilution.

Discussion
Production of recombinant protein is important for subunit vaccine development. Since there is no single universal host, which is perfect for production of all desired recombinant proteins, the selection of the right expression system is pivotal for development of a manufacturing process. The production host is not only important for the correct protein folding (protective antibodies often target conformational epitopes) but also process economics are key to keeping the price of the vaccine as low as possible, especially for vaccines targeting low-income countries.

From a manufacturing perspective, the major challenge with recombinant Pf48/45 is production of correctly folded protein with sufficient yield (reviewed in [3]). One way to increase the amount of properly folded protein has been to produce Pf48/45 in the L. lactis expression system genetically fused to the GLURP-R0 region [14, 15]. The efficient expression of disulfide-bonded protein in L. lactis was unexpected as this organism is low in its cysteine content and lacking known disulfide bond
Fig. 4 Mapping of disulphide-bonds in the Pf48/45-6C region of R0.6C. R0.6C with and without reduction was digested with the protease trypsin prior to LC–MS/MS analysis. Two crosslinked peptides were identified and corresponding mass spectra of each peptide is shown in a and b with mass spectra corresponding to the non-reduced sample in black and the corresponding mass spectra from the reduced sample in blue. The proposed disulfide connectivity is indicated (green dashed lines) based on the extensive MS/MS fragmentation of each peptide (solid black lines). Several control peptides without cysteine residues were analyzed alongside to confirm equal sample load in each analysis, and spectra for one of these in c. Annotated MS/MS spectra of the peptide from a is shown in d. Schematic of the identified disulfide connectivity of Pf48/45-6C in R0.6C is shown in e. The disulfide bonds that have been verified by LC–MS/MS is indicated by a solid black line and disulfide bonds indicated with dashed green lines is one of two possibilities.

Fig. 5 Size exclusion and reversed-phase HPLC analysis of purified R0.6C. a Size exclusion chromatography was performed under native conditions in a phosphate buffer pH 6.7, to determine the amount of monomer in the sample. The peak corresponding to the monomer is indicated with the integrated area of the peak written above. b Reversed-phase HPLC–UV chromatograms recorded following analysis of purified protein batches. The peak at 17 min corresponds to monomeric R0.6C antigen.
forming enzymes [26]. Thus, disulfide bond formation of recombinant Pf48/45 most likely occurs spontaneously after secretion and is not only dependent on the primary structure but also on environmental factors that determine cysteine oxidation. By carefully optimizing the ratio of different redox couples in the fermentation broth, we have identified conditions, which render the extracellular milieu more oxidizing allowing formation of structural disulfide bonds in the Pf48/45-6C domain of the fusion protein. These conditions seem to favor the formation of intramolecular disulfide bonds as secreted R0.6C was mainly present in the monomer state. However, the finding that crude R0.6C shows reduced reactivity with mAb45.1 compared to the reference material consisting of all six cysteine residues in the oxidized state as shown by mass spectrometry analysis. The established disulfide connectivity of R0.6C is in excellent agreement with the disulfide bond connectivity of another recombinant protein containing the Pf48/45-10C region (Mistarz et al., unpublished). The purity of the R0.6C batch is 87% as determined by RP-HPLC. Impurities in the final R0.6C batch are likely, at least in part, product-related consisting of misfolded protein species or degradation products.

Although the final yield of purified recombinant R0.6C is almost 25 mg per L culture broth, we suggest that further improvements are possible. Such improvements may include procedures to increase the biomass through systems where lactate is removed from the culture broth during fermentation using for example the REED™ (Reverse Electro-Enhanced Dialysis) technology [18]. Alternatively, product yield may be increased through adjusting the fermentation process, which is very easy to scale up to 200–1000 L since there is no requirement for

---

**Fig. 6** Immunogenicity of purified R0.6C. Rats were immunized with increasing doses (2.5, 10, and 25 µg) of purified R0.6C. Levels of specific antibodies were measured in the a R0.6C-ELISA, b mAb45.1 competitive ELISA, and c Pf48/45-6C-ELISA. d Relationship between antibody levels determined in the 6C-ELISA and the 45.1 competition ELISA. Antibody titers are expressed as EC50 values. The line represents the median value. P values are based on the Mann–Whitney rank sum test.
oxygen and heavy stirring during fermentation. Finally, product yields can be increased through performing multiple fermentations that can be pooled before downstream purification.

Previously we have investigated the immunogenicity of Pf48/45-based vaccine candidates using immune purified protein [14, 15, 27]. Here, we showed that Pf48/45 fusion protein purified by conventional chromatographic procedures together with Montanide ISA 720 VG elicits TB antibodies at the lowest dose of 2.5 µg. Previously, doses below 4.7 µg failed to elicit TB antibodies when adjuvanted in Alhydrogel [14]. Improved formulations may contain immune modulators [28, 29] or may be based on novel delivery systems including virus-like particles (VLP). This concept has been demonstrated recently for another TBV candidate, Pf625, which was covalently coupled to VLPs [23, 24]. In this context, it is clearly important that the L. lactis expression system is able to accommodate a range of affinity tags added to either end of the recombinant protein.

In conclusion, we have demonstrated that L. lactis microbial factories are highly suited for the production of Pf48/45. A manufacturing process for soluble and correctly folded R0.6C was developed and the resulting vaccine antigen induces high levels of functional antibodies. The high yield of correctly folded protein and the straightforward production process offers the possibility to investigate the vaccine potential of Pf48/45 in human clinical trials.

Methods
Preparation of constructs
All the constructs are based on the L. lactis pSS1 plasmid vector [14]. The R0.6C construct with a C-terminal His tag has been described [14]. Non-tagged R0.6C was generated through PCR with forward primer (5′-GAAT GGA TCC TAC AAG TGA GAA TAG AAA TAA ACG) and reverse primer (5′-GAAT AGA TCT TTA TGC TGA ATC TAT AGT AAC TGT CAT ATA AGC) using R0.6C.6H gene as template. Codon optimized R0.6C.6H and N-terminal SpyCatcher and SpyTag [30] containing BamHI-BglII was synthesized by (GeneArt® Life Technologies, Germany) and inserted into pSS1. For construction of chimeric N-terminal (mSA-R0.6C.6H) or C-terminal (R0.6C-mSA.6H) R0.6C, a synthetic DNA fragment encoding the monomeric Streptavidin (mSA) (GeneBank: 4JNJ_A) with a small Gly–Gly–Ser linker was synthesized by (GeneArt® Life Technologies) and cloned into R0.6C.6H. The USP45-R0.6C.6H construct was generated by replacing the mutD310 signal peptide in pSS1 with the USP45 signal peptide [31] synthesized by (GeneArt® Life Technologies) and cloned into R0.6C. All the constructs were verified by sequencing and subsequently transformed into L. lactis MG1363 by electroporation as described [32].

Screening, fermentation and protein purification
L. lactis MG1363, containing R0.6C constructs was grown overnight at 30 °C in 5 ml LAB medium [15] supplemented with 4% glycerol–phosphate, 5% glucose and 5 µg/ml erythromycin. Culture supernatants were clarified by centrifugation at 9000g for 20 min and analysis of all the constructs was performed by Coomassie stained SDS-PAGE gel and Western blotting with mAb45.1 against conformational epitope I. Fermentation of L. lactis MG1363/R0.6C.6H was performed in a 1 l lab scale bioreactor at 30 °C with gentle stirring (150 rpm). For the time-course experiment 10 ml samples were withdrawn and used for analysis. Optical density at 600 nm (OD600) was used to test cell density. Cell-free culture-filtrates were concentrated tenfold and buffer exchanged into phosphate buffered saline (PBS) pH 7.4 supplemented with 15 mM imidazole using a QuixStand Benchtop system (Hollow fiber cartridge with cutoff at 50,000 Da, surface area 650 cm², GE Healthcare, Sweden) followed by filtration through a Durapore filter (PVDF, 0.22 µm, Millipore) and applied to a 5 ml HisTrap HP column (GE Healthcare, Sweden). Bound protein was step gradient eluted with 500 mM imidazole in tris buffer pH 8.0 (55 mM tris, 21 mM NaCl) at a flow rate of 4 ml/min and fractions containing the desired protein were applied to a 5 ml HiTrap Q HP column (GE Healthcare, Sweden). Bound protein was eluted through step gradient elution in tris buffer pH 8.0 (55 mM tris, 1 M NaCl) and fractions containing monomers with the highest amount of mAb45.1-reactive protein were concentrated by a VIVA spin column 30 kDa cutoff (GE Healthcare, Sweden), and kept in 55 mM tris, 300 mM NaCl 0.025% Tween 80 and 1 mM EDTA, pH 8.0 at ~80 °C until use. Immune purification of R0.6C was performed as described earlier [14, 15]. Analysis of all the fractions was performed by SDS-PAGE. Immunoblotting was performed with mAb45.1 against conformational epitope I. Protein concentration was measured using either the BCA protein assay (Thermo Fisher Scientific) or by densitometric analysis of Coomassie stained SDS-PAGE gel using Image Quant TL (IQTL) software (GE Healthcare).

SEC-HPLC and RP-HPLC analysis of R0.6C
Native size exclusion high-performance liquid chromatography (SEC-HPLC) or reversed-phase HPLC (RP-HPLC) of intact R0.6C were performed using an Agilent 1100 Series HPLC System (Agilent Technologies, USA) equipped with a TSKgel G3000SWXL SEC column, 5 µm, 7.8 × 300 mm (Tosoh Bioscience, Japan) or equipped with a Vydac 214TP C4 reversed-phase column, 5 µm, 4.6 × 250 mm
immunizations complied with European and National regulations. Groups of eight rats were immunized by the s.c. route 3 times at 3-week intervals with increasing doses (2.5, 10, and 25 μg) of R0.6C. Protein preparations were emulsified in Montanide ISA720 VG (Seppic) immediately before use. Responses were measured using sera taken three weeks after the third immunization (Day 63).

### Enzyme-linked immunosorbent assay (ELISA)

The mAb45.1 sandwich ELISA was performed as previously described [14, 15]. The coating concentration of recombinant Pf648/45 (6C) and R0.6C was 0.5 μg/ml and bound antibodies were detected with HRP-conjugated rabbit-anti rat IgG-HRP (DAKO, Denmark) as described in detail [27]. The mAb45.1 competition ELISA was performed as follows; Briefly, ELISA MaxiSorp microtitre plates (Sterilin® ELISA plates, The Netherlands) were coated at 4 °C overnight with 100 μl per well of 5 μg/ml of mAb45.1 in PBS pH 7.4. Wells were blocked with 150 μl of 5% non-fat skimmed milk powder in PBS for 1 h followed by three washings with PBS containing 0.05% Tween 20 (PBST). Sera at threefold dilutions (50 μl) were mixed with 50 μl R0.6C (1 μg/ml) in PBST, added to the wells and incubated for 4 h at room temperature. Wells were washed with PBST and bound antigen was revealed with anti-His-HRP (1/6000 in PBST) for 2 h at room temperature. Midpoint (EC50) values were calculated using GraphPad Prism 7, (GraphPad Software, USA).

### Standard membrane feeding assay (SMFA)

The biological activity of anti-R0.6C antibodies was assessed in the SMFA as previously described in detail [15]. Estimates of transmission reducing activity (TRA) were generated using oocyst densities in individual mosquitoes, comparing test feeders with control feeders from the same experiment as described [33].

### Statistical analysis

The Mann–Whitney rank sum test was used for analyzing differences between groups. P < 0.05 was considered to be statistically significant.

### Additional files

**Additional file 1.** Production and purification of R0.6C.

**Additional file 2.** Intact mass analysis of R0.6C. Mass spectra of full-length antigens by LC–MS and peptide maps from LC–MS/MS of trypsin digested antigens. (a) Deconvoluted mass spectra of non-reduced R0.6C. (b) Deconvoluted mass spectra of reduced R0.6C. (c) Tryptic peptide maps of R0.6C. In brackets is the calculated accuracy of the measurement to the predicted mass in ppm. All measurements were done in duplicates.

**Additional file 3.** Stability of R0.6C. R0.6C was incubated at 4 °C for 0, 15 and 30 days. Three and 1 μg of R0.6C, with (+) and without (−) DTT was analyzed by (a) SDS-PAGE coomassie staining, (b) Immune-blotting using mAb45.1 and (c) Sandwich ELISA. Antigens were captured with mAb45.1 and detected with anti-His-HRP.
Abbreviations
6C: 6-Cys-region of the Plasmodium falciparum s48/45 protein; DTT: dithiothreitol; GLURP: glutamate-rich protein of Plasmodium falciparum; MSP3: merozoite surface protein 3 of Plasmodium falciparum; IEC: ion exchange chromatography; IMAC: immobilized metal ion chromatography; LC–MS: liquid chromatography coupled with mass spectrometry; LC–MS/MS: liquid chromatography–mass spectrometry; mAb45.1: antibody binding 45.1 (epitope I) of the Plasmodium falciparum 48/45 protein; Pf48/45: Plasmodium falciparum s48/45 protein; RD: r0-region of the glutamate-rich protein (GLURP); SEC: analytical size-exclusion chromatography of intact proteins under native conditions; SMFA: standard membrane feeding assay; TB: transmission-blocking; XL: cross-linked peptide.

Authors’ contributions
SKS, RWS and MT designed the study. SKS, RWS, UHM, BKC, FY, KDR collected the data. MT, SKS, RWS, UHM, and KDR wrote the manuscript. All authors read and approved the final manuscript.

Author details
1 Department for Congenital Disorders, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen, Denmark. 2 Department of International Health, the Danish Council for Strategic research (Grants 13127). This work was funded in part by the PATH Malaria Vaccine Initiative and by the Danish Animal Experiments Inspectorate. Approval Number: 2013-15-2934-00902/BES.

Availability of data and materials
The datasets on which the findings and conclusions of this article is based upon are all included in this manuscript and the Additional files 1, 2, 3 associated with it.

Ethics approval
The animal studies were approved by the Danish Animal Experiments Inspectorate. Approval Number: 2013-15-2934-00902/BES.

Funding
This work was funded in part by the PATH Malaria Vaccine Initiative and by the Danish Council for Strategic research (Grants 13127).

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 7 February 2017   Accepted: 26 May 2017

References
1. Schneider P, Bousema T, Omar S, Gouagna L, Sawo P, Schallig H, Sauerwein R. (Sub)microscopic Plasmodium falciparum gametocytaemia in Kenyan children after treatment with sulphadoxine-pyrimethamine monotherapy or in combination with artesunate. Int J Parasitol. 2006;36:403–8.
2. Alonso PL, Bounoun G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F, Doutombo OK, Greenwood B, Hall BF, Levine MM. A research agenda to underpin malaria eradication. PLOS Med. 2011;8:e1000406.
3. Theisen M, Jore MM, Sauerwein R. Towards clinical development of a Pf48/45-based transmission blocking malaria vaccine. Expert Rev Vaccines. 2017;16(4):329–36.
4. Ouchtchoukov N, Vermunt A, Jansen J, Kaan A, Roeffen W, Teelen K, Lasonder E, Braks A, van de Vege-Bolmer M, Qiu LY, et al. Epitope analysis of the malaria surface antigen Pf48/45 identifies a sub-domain that elicits transmission blocking antibodies. J Biol Chem. 2007;282:17148–56.
5. Vermeulen AN, Ponnudurai T, Beckers PJ, Verhave JP, Smits MA, Meuwissen JH. Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible for transmission-blocking antibodies in the mosquito. J Exp Med. 1985;162:1460–76.
6. Carter R, Graves PM, Keister DB, Quakyi IA. Properties of epitopes of Pf 48/45, a target of transmission blocking monoclonal antibodies, on gametes of different isolates of Plasmodium falciparum. Parasite Immunol. 1990;12:587–603.
7. Rener J, Graves PM, Carter R, Williams JL, Burkat TR. Target antigens of transmission-blocking immunity on gametes of plasmodium falciparum. J Exp Med. 1985;158:976–81.
8. Ponnudurai T, Lenssen AH, Van Gemert GJ, Bensink MP, Bolmer M, Meuwissen JH. Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes. Parasitology. 1989;98(Pt 2):165–73.
9. Kocken CH, Jansen J, Kaan AM, Beckers PJ, Ponnudurai T, Kaslow DC, Konings RN, Schoenmakers JG. Cloning and expression of the gene coding for the transmission blocking target antigen Pf48/45 of Plasmodium falciparum. Mol Biochem Parasitol. 1993;61:59–68.
10. Milek RL, DeVries AA, Roeffen WE, Stunnenberg H, Rottier PJ, Konings RN. Plasmodium falciparum: heterologous synthesis of the transmission-blocking vaccine candidate Pf48/45 in recombinant vaccinia virus-infected cells. Exp Parasitol. 1998;90:165–74.
11. Milek RL, Stunnenberg HG, Konings RN. Assembly and expression of a synthetic gene encoding the antigen Pf48/45 of the human malaria parasite Plasmodium falciparum in yeast. Vaccine. 2000;18:1402–11.
12. Jones CS, Luong T, Hannon M, Tran M, Gregory JA, Shen Z, Briggs SP, Mayfield SP. Heterologous expression of the C-terminal antigenic domain of the malaria vaccine candidate Pf48/45 in the green alga Chlamydomonas reinhardtii. Appl Microbiol Biotechnol. 2013;97:1987–95.
13. Prakhnevsky A, Mamedov T, Leffert B, Rahimova R, Ghosh A, Mett V, Yusibov V. Development of a single-replicon miniBYV vector for co-expression of heterologous proteins. Mol Biotechnol. 2015;57:1011–10.
14. Singh SK, Roeffen W, Andersen G, Bousema T, Christiansen M, Sauerwein R, Theisen M. A Plasmodium falciparum 48/45 single epitope R0.6C subunit protein elicits high levels of transmission blocking antibodies. Vaccine. 2015;33:1981–6.
15. Theisen M, Roeffen W, Singh SK, Andersen G, Amoah L, van de Vege-Bolmer M, Arens T, Tiendrebegro RW, Jones S, Bousema T, et al. A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages. Vaccine. 2014;32:2623–30.
16. Bermudez-Humaran LG, Langella P, Cortes-Perez NG, Gruss A, Tamez-Guerra RS, Oliveira SC, Saucedo-Cardenas O, de Oca-Luna RM, Le Loir Y. Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production. Infect Immun. 2003;71:1887–96.
17. Bosma T, Kannenga R, Neef J, Audouy SA, van Roosmalen ML, Steen A, Buist G, Kok J, Kupfers OP, Robillard G, Leenhouts K. Novel surface display system for proteins on non-genetically modified gram-positive bacteria. Appl Environ Microbiol. 2006;72:880–9.
18. Jorgensen OA, Wang A, Madsen SM. Recombinant protein expression in Lactococcus lactis using the P170 expression system. FEMS Microbiol Lett. 2014;351:170–8.
19. Belard S, Issifou S, Hounkpatin AB, Schaumburg F, Ngoa UA, Esen M, Fendel R, de Salazar PM, Murbeth RE, Milligan P, et al. A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children. PLoS ONE. 2011;6:e22525.
20. Esen M, Kremsner PG, Schleucher R, Gassler M, Imbault N, Leroy O, Jepsen S, Knudsen BW, Schumm M, et al. Safety and immuno-nogenicity of GMZ2—a MSP3/GLURP fusion protein malaria vaccine candidate. Vaccine. 2009;27:6862–8.
22. Sirima SB, Mordmuller B, Milligan P, Ngoa UA, Kironde F, Atuguba F, Tiono AB, Issifou S, Kaddumukasa M, Bangre O, et al. A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children. Vaccine. 2016;34:4536–42.

23. Thrane S, Janitzeck CM, Matondo S, Resende M, Gustavsson T, de Jongh WA, Clemmensen S, Roefen W, van de Vege-Bolmer M, van Gemert GJ, et al. Bacterial superglue enables easy development of efficient virus-like particle based vaccines. J Nanobiotechnol. 2016;14:30.

24. Brune KD, Leneghan DB, Brian IJ, Ishizuka AS, Bachmann MF, Draper SJ, Biswas S, Howarth M. Plug-and-display: decoration of virus-like particles via isopeptide bonds for modular immunization. Sci Rep. 2016;6:19234.

25. Pritsch M, Ben-Khaled N, Chaloupka M, Kobold S, Bereiss-Riha N, Peter A, Liegl G, Schubert S, Hoelscher M, Loscher T, Wieser A. Comparison of intranasal outer membrane vesicles with cholera toxin and injected MF59C.1 as adjuvants for malaria transmission blocking antigens AnAPN1 and Pfs48/45. J Immunol Res. 2016;2016:3576028.

26. Daniels R, Mellroth P, Bernsel A, Neiers F, Normark S, von Heijne G, Henriques-Normark B. Disulfide bond formation and cysteine exclusion in gram-positive bacteria. J Biol Chem. 2010;285:3300–9.

27. Roefen W, Theisen M, van de Vege-Bolmer M, van Gemert G, Arens T, Andersen G, Christiansen M, Sevgave L, Singh SK, Kaviraj S, Sauerwein R. Transmission-blocking activity of antibodies to Plasmodium falciparum GLURP:10C chimeric protein formulated in different adjuvants. Malar J. 2015;14:443.

28. Baldwin SL, Roefen W, Singh SK, Tiendrebeogo RW, Christiansen M, Beebe E, Carter D, Fox CB, Howard RF, Reed SG, et al. Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen. Vaccine. 2016;34(19):2207–15.

29. Lousada-Dietrich S, Jodgand PS, Jepsen S, Pinto VV, Ditlev SB, Christiansen M, Larsen SO, Fox CB, Raman VS, Howard RF, et al. A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2–a GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine. 2011;29:3284–92.

30. Veggianni G, Zakeri B, Howarth M. Superglue from bacteria: unbreakable bridges for protein nanotechnology. Trends Biotechnol. 2014;32:506–12.

31. Ng DT, Sarkar CA. Engineering signal peptides for enhanced protein secretion from Lactococcus lactis. Appl Environ Microbiol. 2013;79:347–56.

32. Holo H, Nes IF. Transformation of Lactococcus by electroporation. Methods Mol Biol. 1995;47:195–9.

33. Churcher TS, Blagborough AM, Delves M, Ramakrishnan C, Kapulu MC, Williams AR, Biswas S, Da DF, Cohuet A, Sinden RE. Measuring the blockade of malaria transmission—an analysis of the standard membrane feeding assay. Int J Parasitol. 2012;42:1037–44.